TEST:

Esopredict™ test

These results confirm that Esopredicts highly reproducible and accurate across risk categories, to stratify BE patients into low, low moderate, high moderate, or high risk for developing HGD or EAC within 5 years.

"Previse said on Thursday that it has been awarded a $1.8 million grant from the National Institutes of Health to support additional clinical testing of Esopredict, the company's recently launched laboratory-developed real-time PCR test for esophageal cancer risk."

Among 41 patients comprising 105 spatially profiled samples, 21 were non-progressors, and 20 were progressors. Based on each patient’s highest risk score, Esopredict had a sensitivity of 100% and specificity of 67%, with 0 true progressors classified as low-risk. Among 14 patients comprising 54 temporally profiled samples, 7 were non-progressors, and 7 were progressors.

"Previse...announced details on Monday, May 8, of two studies presented during Digestive Disease Week® 2023, held May 6-9 in Chicago. Both analyses clinically validate use of biomarkers to detect and assess risk of esophageal cancer developing in patients with Barrett’s esophagus."

This epigenetic biomarker model has value as a laboratory-developed test to predict future risk of neoplastic progression in BE patients. In our test set, 90% of progressors fell into medium or high risk categories, with 54% in high risk. The ability to risk-stratify BE patients can improve care management by finding high-risk patients who may benefit from increased surveillance or intervention, but also finding low-risk patients who may not need as frequent surveillance.

"Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™....In addition to launching Esopredict™, Previse also raised a $3M seed round, with participation from TEDCO, Wexford Science and Technology, Riptide Ventures, Gaingels, and numerous angel investors."